 |
32 Diseases |  |
11 Trials |
|
11 Trials |  |
1696 News |  |
| «12...9101112131415161718192021» |
- | Prezista (darunavir) / J&J
Journal: Enhanced oral bioavailability and brain uptake of Darunavir using lipid nanoemulsion formulation. (Pubmed Central) - Jun 5, 2019
The higher bioavailability of Darunavir from nanoemulsion could lessen the dose related side effects. Moreover, high organ distribution results in passive uptake of Darunavir to HIV reservoir organs.
- | Prezista (darunavir) / J&J
Journal: Stability and compatibility of ondansetron with haloperidol in parenteral admixtures. (Pubmed Central) - Jun 4, 2019
25% of the samples show a higher loss at 24 hours, and the chemical stability of these samples is 12 hours. The stability and compatibility of OND and HAL in the coadministered admixtures in Viaflo plastic bags with normal saline or dextrose are suggested at 12 hours.
- | Prezista (darunavir) / J&J, Epivir (lamivudine) / ViiV Healthcare, Reyataz (atazanavir sulfate) / BMS
Clinical, Observational data, Journal: Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort. (Pubmed Central) - May 29, 2019
The stability and compatibility of OND and HAL in the coadministered admixtures in Viaflo plastic bags with normal saline or dextrose are suggested at 12 hours. No abstract available
- | Prezista (darunavir) / J&J
Clinical, Journal: Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study). (Pubmed Central) - May 29, 2019
No abstract available Dual therapy with RPV + DRVb proved to be effective and safe in patients with advanced HIV infection, long exposure to ART, low CD4 nadir, previous virologic failure, and/or history of ineffective ART.
- | Prezista (darunavir) / J&J
Clinical, Journal: Nanoparticle-in-Microparticle Oral Drug Delivery System of a Clinically Relevant Darunavir/Ritonavir Antiretroviral Combination. (Pubmed Central) - May 24, 2019
In this work, we developed a sequential nanoprecipitation method for the production of pure nanoparticles of DRV and its boosting agent ritonavir in a clinically relevant 8:1 weight ratio using alginate as viscosity stabilizer and used this nanosuspension to produce a novel kind of nanoparticle-in-microparticle delivery system that was fully characterized and the pharmacokinetics assessed in rats. The most significant points of the current manuscript are.
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) - May 24, 2019
P4, N=300, Not yet recruiting, Sponsor: Kirby Institute
The most significant points of the current manuscript are. Initiation date: Apr 2019 --> Jul 2019
- | Enrollment status: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - May 16, 2019
P1, N=200, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Initiation date: Apr 2019 --> Jul 2019 Enrolling by invitation --> Recruiting
- | Prezista (darunavir) / J&J, Reyataz (atazanavir sulfate) / BMS
Clinical, Clinical data: Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study. (Pubmed Central) - May 15, 2019
In this observational study, the two main HIV PIs currently recommended by perinatal guidelines showed similar safety and activity in pregnancy, with no evidence of differences between the two drugs in terms of main pregnancy outcomes. Based on the minor differences observed in laboratory measures, prescribing physicians might prefer either drug in some particular situations where the different impacts of treatment on lipid profile and bilirubin may have clinical relevance.
- | Prezista (darunavir) / J&J, Spherazole (itraconazole) / RA Chem, JW Pharma, Spherics
Clinical, Journal, Adverse events: Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis. (Pubmed Central) - May 15, 2019
Based on the minor differences observed in laboratory measures, prescribing physicians might prefer either drug in some particular situations where the different impacts of treatment on lipid profile and bilirubin may have clinical relevance. No abstract available
- | Journal: Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial. (Pubmed Central) - May 15, 2019
Compliance issues, maraviroc-darunavir interaction and raltegravir-darunavir interaction were suspected and may affect the kinetics of viral decay during pentatherapy. A specific pharmacokinetic interaction study is needed to explore the interactions between darunavir and maraviroc and raltegravir.
- | Prezista (darunavir) / J&J
Clinical, Journal: Characteristics of Treatment-Experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment. (Pubmed Central) - May 15, 2019
Better understanding of the current approaches to pediatric ART sequencing in resource-limited settings is needed.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
- | Prezista (darunavir) / J&J, Reyataz (atazanavir sulfate) / BMS
Journal: Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. (Pubmed Central) - May 7, 2019
The work cannot be changed in any way or used commercially without permission from the journal. Although confounding by indication and calendar year cannot be completely ruled out, in ART-experienced subjects the long-term effectiveness of DRV/r-containing regimens appears to be greater than that of ATZ/r and LPV/r.
- | Prezista (darunavir) / J&J, Reyataz (atazanavir sulfate) / BMS
Clinical, Journal: Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. (Pubmed Central) - May 1, 2019
Causal inference is limited by the observational nature of the D:A:D study. Our findings should prompt investigation into the possible underlying mechanisms of this finding.
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / GSK, ViiV Healthcare
Journal: Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction between cobicistat and intrabursal triamcinolone. (Pubmed Central) - May 1, 2019
This is the first report to describe this predictable DDI with cobicistat following intrabursal glucocorticoid injection. This case highlights the complexities in managing non-HIV-related chronic morbidities in people living with HIV.
- ||| Prezista (darunavir) / J&J, Isentress (raltegravir) / Merck (MSD)
Clinical, Adverse events: @PaulSaxMD Hi Paul. Bit of an unusual clinical question. Have you seen breast enlargement as a side effect of raltegravir or Darunavir before? In the absence of other major lipodystrophy. Talking marked increase over 1 year, and interferes with pt QoL. #IDtwitter (Twitter) - May 1, 2019
- | Prezista (darunavir) / J&J
Journal: Long-Chain Triglycerides-based Self-Nanoemulsifying Oily Formulations (SNEOFs) of Darunavir with Improved Lymphatic Targeting Potential. (Pubmed Central) - Apr 26, 2019
Also, in vivo pharmacokinetic studies in rat corroborated significant improvement in rate and extent of drug absorption into plasma vis-à-vis pure drug. In a nutshell, these studies indicate significant improvement in the biopharmaceutical attributes of a robust and stable SNEOFs formulation of darunavir for holistic management of viral loads in lymph and blood.
- | Isentress (raltegravir) / Merck (MSD)
Trial termination: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Apr 19, 2019
P2, N=11, Terminated, Sponsor: Merck Sharp & Dohme Corp.
In a nutshell, these studies indicate significant improvement in the biopharmaceutical attributes of a robust and stable SNEOFs formulation of darunavir for holistic management of viral loads in lymph and blood. Completed --> Terminated; This study was terminated early due to poor recruitment.
- | Journal: Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2017). (Pubmed Central) - Apr 19, 2019
We present the reasons and criteria for switching ART in patients with an undetectable PVL and in those who present virological failure, in which case salvage ART should include 3 (or at least 2) drugs that are fully active against HIV. We also update the criteria for ART in specific situations (acute infection, HIV-2 infection, pregnancy) and comorbidities (tuberculosis or other opportunistic infections, kidney disease, liver disease and cancer).
- | Prezista (darunavir) / J&J
Clinical, Journal: HIV-1 drug resistance testing at second-line regimen failure in Arua, Uganda: avoiding unnecessary switch to an empiric third-line. (Pubmed Central) - Apr 18, 2019
Our study highlights the need for access to drug resistance tests to avoid unnecessary switches to third-line therapy, but also for access to third-line drugs, in particular integrase inhibitors. Low nadir CD4 count might be an indicator of third-line drug requirement for patients failing second-line therapy.
- | Prezista (darunavir) / J&J
Journal: Correction to Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease. (Pubmed Central) - Apr 18, 2019
Low nadir CD4 count might be an indicator of third-line drug requirement for patients failing second-line therapy. No abstract available
- | Prezista (darunavir) / J&J
Trial completion date, Trial primary completion date: Optimization of Darunavir Therapy and Dosage Recommendations (clinicaltrials.gov) - Apr 18, 2019
P4, N=127, Active, not recruiting, Sponsor: Universit
No abstract available Trial completion date: Mar 2019 --> Jul 2019 | Trial primary completion date: Mar 2019 --> Jul 2019
- || Prezista (darunavir) / J&J
Great number of Irish posters at #ECCMID2019 but this Italian poster might be my favourite. Association between epicardial adipose tissue and Darunavir exposure. (Twitter) - Apr 14, 2019
- Prezista (darunavir) / J&J, ritonavir / Generic mfg.
Epicardial adipose tissue and use of contemporary inhibitors in people living with HIV () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1300;
Background: The cumulative exposure to ritonavir-boosted-darunavir (DRV/r) has been recently associated to an increased risk of cardiovascular disease in HIV-patients, but the possible pathogenic mechanism remains unclear. In conclusion, our study suggests that the association between duration of DRV/r exposure and increased risk for cardiovascular events in HIV patients on antiretroviral therapy could be at least in part accounted by a drug induced modification of EAT deposition.
- Prezista (darunavir) / J&J
Efficacy and safety of darunavir-ritonavir 1200/100mg once daily for the treatment of HIV-1 Infection: DARONCE study () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1194;
In conclusion, our study suggests that the association between duration of DRV/r exposure and increased risk for cardiovascular events in HIV patients on antiretroviral therapy could be at least in part accounted by a drug induced modification of EAT deposition. DRV-r 1200/100mg once daily evidenced high efficacy in viral suppression and safety, proving to be a viable option to achieve undetectable CV without causing toxicity.
- ||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: BRAAVE 2020: Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (clinicaltrials.gov) - Mar 29, 2019
P3b, N=496, Active, not recruiting, Sponsor: Gilead Sciences
DRV-r 1200/100mg once daily evidenced high efficacy in viral suppression and safety, proving to be a viable option to achieve undetectable CV without causing toxicity. Recruiting --> Active, not recruiting
- | Prezista (darunavir) / J&J, Reyataz (atazanavir sulfate) / BMS
Clinical, Journal: Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. (Pubmed Central) - Mar 29, 2019
Recruiting --> Active, not recruiting A switch to ATV/r or DRV/r may result in more rapid reduction in TC and the TC:HDL-C ratio in PHIV youth, potentially impacting long-term cardiovascular disease risk.
- | Prezista (darunavir) / J&J
estes merdas reps.virem-se para a peste trampas e deixem a Russia em páz (Twitter) - Mar 24, 2019
- | Biomarker, Journal: Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. (Pubmed Central) - Mar 23, 2019
Associations of plasma HDLox and LDLox with ΔCIMT were not apparent. While plasma levels of abnormal lipoproteins have been shown to be associated with CVD outcomes, clear associations with sub-clinical atherosclerosis progression were not apparent in our study.
- |||| Prezista (darunavir) / J&J, Intelence (etravirine) / J&J, Isentress (raltegravir) / Merck (MSD)
Trial completion, Combination therapy: A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (clinicaltrials.gov) - Mar 15, 2019
P4, N=545, Completed, Sponsor: AIDS Clinical Trials Group
While plasma levels of abnormal lipoproteins have been shown to be associated with CVD outcomes, clear associations with sub-clinical atherosclerosis progression were not apparent in our study. Active, not recruiting --> Completed
- | Enrollment change: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 6, 2019
P1, N=200, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed N=40 --> 200
- | Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date, Trial primary completion date: PEP2: Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis. (clinicaltrials.gov) - Feb 7, 2019
P1, N=58, Recruiting, Sponsor: Emory University
N=40 --> 200 Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) - Feb 7, 2019
P4, N=300, Not yet recruiting, Sponsor: Kirby Institute
Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019 Initiation date: Jan 2019 --> Apr 2019
- ||| rovafovir etalafenamide (GS-9131) / Gilead
Enrollment change, Monotherapy: Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus (clinicaltrials.gov) - Jan 31, 2019
P2, N=68, Active, not recruiting, Sponsor: Gilead Sciences
Initiation date: Jan 2019 --> Apr 2019 N=11 --> 68
- | Trial completion date, Trial primary completion date: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Dec 21, 2018
P1, N=40, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=11 --> 68 Trial completion date: Dec 2018 --> Feb 2022 | Trial primary completion date: Dec 2018 --> Feb 2022
- ||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date: Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (clinicaltrials.gov) - Dec 11, 2018
P3, N=578, Active, not recruiting, Sponsor: Gilead Sciences
Trial completion date: Dec 2018 --> Feb 2022 | Trial primary completion date: Dec 2018 --> Feb 2022 Trial completion date: Jul 2019 --> Jul 2020
- | Trial completion: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Dec 4, 2018
P3, N=224, Completed, Sponsor: University Hospital, Tours
Trial completion date: Jul 2019 --> Jul 2020 Active, not recruiting --> Completed
- ||| rovafovir etalafenamide (GS-9131) / Gilead
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Monotherapy: Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus (clinicaltrials.gov) - Dec 3, 2018
P2, N=11, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=58 --> 11 | Trial completion date: Nov 2019 --> Aug 2020 | Trial primary completion date: Dec 2018 --> Mar 2020
- | Prezista (darunavir) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: Optimization of Darunavir Therapy and Dosage Recommendations (clinicaltrials.gov) - Nov 14, 2018
P4, N=127, Active, not recruiting, Sponsor: Universit
Recruiting --> Active, not recruiting | N=58 --> 11 | Trial completion date: Nov 2019 --> Aug 2020 | Trial primary completion date: Dec 2018 --> Mar 2020 Recruiting --> Active, not recruiting | Trial completion date: Sep 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) - Sep 18, 2018
P4, N=300, Not yet recruiting, Sponsor: Kirby Institute
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: BRAAVE 2020: Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (clinicaltrials.gov) - Sep 14, 2018
P3b, N=480, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial completion date: Sep 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019 Not yet recruiting --> Recruiting
- | Enrollment change: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Sep 13, 2018
P1, N=40, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting --> Recruiting N=20 --> 40
- | Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (clinicaltrials.gov) - Aug 15, 2018
P2/3, N=100, Recruiting, Sponsor: Gilead Sciences
N=20 --> 40 Trial primary completion date: Jul 2018 --> Jul 2020
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: BRAAVE 2020: Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (clinicaltrials.gov) - Aug 14, 2018
P3b, N=480, Not yet recruiting, Sponsor: Gilead Sciences
- | Prezista (darunavir) / J&J, zidovudine / Generic mfg.
Journal: Metabolic health across the body mass index spectrum in HIV-Infected and HIV-Uninfected Men. (Pubmed Central) - Jul 12, 2018
Metabolically healthy obesity prevalence does not differ by HIV serostatus. However, among nonobese men, HIV infection is associated with lower metabolic health prevalence, with associations between lack of metabolic health and darunavir and thymidine analog nucleoside reverse transcriptase inhibitor exposure observed.
- | Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date: Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (clinicaltrials.gov) - Jul 11, 2018
P3, N=668, Active, not recruiting, Sponsor: Gilead Sciences
However, among nonobese men, HIV infection is associated with lower metabolic health prevalence, with associations between lack of metabolic health and darunavir and thymidine analog nucleoside reverse transcriptase inhibitor exposure observed. Trial completion date: May 2018 --> Jan 2019
- ||| Enrollment open, Trial initiation date: RESIST-2: 2nd-line ART for HIV-2 Infection (clinicaltrials.gov) - Jul 6, 2018
P=N/A, N=150, Recruiting, Sponsor: University of Washington
Trial completion date: May 2018 --> Jan 2019 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Jul 2018
- ||| Prezista (darunavir) / J&J, Isentress (raltegravir) / Merck (MSD)
Trial completion, Enrollment change: Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi) (clinicaltrials.gov) - Jul 2, 2018
P=N/A, N=360, Completed, Sponsor: Asociacion para el Estudio de las Enfermedades Infecciosas
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Jul 2018 Recruiting --> Completed | N=201 --> 360
- | Prezista (darunavir) / J&J
New trial: Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients (clinicaltrials.gov) - May 8, 2018
P=N/A, N=60, Recruiting, Sponsor: Centre Hospitalier Universitaire Vaudois
- ||| Prezista (darunavir) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J
Trial completion: ST.O.RE.: Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta) (clinicaltrials.gov) - Apr 24, 2018
P=N/A, N=337, Completed, Sponsor: Janssen-Cilag S.p.A.
Recruiting --> Completed | N=201 --> 360 Active, not recruiting --> Completed
- |||| rovafovir etalafenamide (GS-9131) / Gilead
Enrollment open, Monotherapy: Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus (clinicaltrials.gov) - Apr 19, 2018
P2, N=58, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting